HighTide Therapeutics (HKG:2511) booked a loss attributable to owners of 120.3 million yuan for the first half of 2025, compared with a loss of 211 million yuan a year earlier, according to a Monday Hong Kong bourse filing.
Shares of the biopharmaceutical firm gained over 7% in Tuesday late-afternoon trade.
Loss per share came in at 0.27 yuan, compared with 0.47 yuan in the prior-year period.
The company said that no revenue was derived during the six months ended June 30.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.